Expression profile of the matricellular protein osteopontin in primary open-angle glaucoma and the normal human eye

Investigative Ophthalmology and Visual Science

Volumn 52, Issue 9, 2011, Pages 6443-6451

  Chowdhury, Uttio Roy ^a   Jea, Seung Youn ^b   Oh, Dong Jin ^b   Rhee, Douglas J ^b   Fautsch, Michael P ^a  

^a MAYO CLINIC   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OSTEOPONTIN;

ADULT; ANIMAL TISSUE; AQUEOUS HUMOR; ARTICLE; CILIARY BODY; CLINICAL ARTICLE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CORNEA ENDOTHELIUM; CORNEA EPITHELIUM; CORNEA THICKNESS; DEGLYCOSYLATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFANT; INTRAOCULAR PRESSURE; IRIS; MALE; MOUSE; NONHUMAN; OCULOPLETHYSMOGRAPHY; OPEN ANGLE GLAUCOMA; OPTIC NERVE; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RETINA; TRABECULAR MESHWORK; VITREOUS BODY; WESTERN BLOTTING; AGED; ANIMAL; C57BL MOUSE; DONOR; EYE; GENE INACTIVATION; GENETICS; GLYCOSYLATION; METABOLISM; MIDDLE AGED; PHYSIOLOGY;

AGED, 80 AND OVER; ANIMALS; AQUEOUS HUMOR; BLOTTING, WESTERN; ENZYME-LINKED IMMUNOSORBENT ASSAY; EYE; FEMALE; GENE EXPRESSION PROFILING; GENE KNOCKOUT TECHNIQUES; GLAUCOMA, OPEN-ANGLE; GLYCOSYLATION; HUMANS; IMMUNOHISTOCHEMISTRY; INTRAOCULAR PRESSURE; MALE; MICE; MICE, INBRED C57BL; MICROSCOPY, CONFOCAL; MIDDLE AGED; OSTEOPONTIN; TISSUE DONORS; TOMOGRAPHY, OPTICAL COHERENCE; TONOMETRY, OCULAR; TRABECULAR MESHWORK; YOUNG ADULT;

EID: 80054014123     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.11-7409     Document Type: Article

References (74)

1. Grant WM. Experimental aqueous perfusion in enucleated human eyes. Arch Ophthalmol. 1963;69:783-801.
2. Acott TS, Kelley MJ. Extracellular matrix in the trabecular meshwork. Exp Eye Res. 2008;86:543-561.
3. Tamm ER, Fuchshofer R. What increases outflow resistance in primary open-angle glaucoma? Surv Ophthalmol. 2007;52(suppl 2):S101-S104.
4. Bahler CK, Howell KG, Hann CR, Fautsch MP, Johnson DH. Prostaglandins increase trabecular meshwork outflow facility in cultured human anterior segments. Am J Ophthalmol. 2008;145:114-119.
5. Oh D-J, Martin JL, Williams AJ, Russell P, Birk DE, Rhee DJ. Effect of latanoprost on the expression of matrix metalloproteinases and their tissue inhibitors in human trabecular meshwork cells. Invest Ophthalmol Vis Sci. 2006;47:3887-3895.
6. Sagara T, Gaton DD, Lindsey JD, Gabelt BT, Kaufman PL, Weinreb RN. Topical prostaglandin F2 treatment reduces collagen types I, III, and IV in the monkey uveoscleral outflow pathway. Arch Ophthalmol. 1999;117:794-801.
7. Toris CB, Gabelt BT, Kaufman PL. Update on the mechanism of action of topical prostaglandins for intraocular pressure reduction. Surv Ophthalmol. 2008;53:S107-S120.
8. Denhardt DT, Giachelli CM, Rittling SR. Role of osteopontin in cellular signaling and toxicant injury. Annu Rev Pharmacol Toxicol. 2001;41:723-749.
9. Denhardt DT, Noda M, O'Regan AW, Pavlin D, Berman JS. Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest. 2001;107:1055-1061.
10. Rhee DJ, Haddadin RI, Kang MH, Oh DJ. Matricellular proteins in the trabecular meshwork. Exp Eye Res. 2009;88:694-703.
11. Sodek J, Batista Da Silva AP, Zohar R. Osteopontin and mucosal protection. J Dent Res. 2006;85:404-415.
12. Haddadin RI, Oh DJ, Kang MH, et al. SPARC-null mice exhibit lower intraocular pressures. Invest Ophthalmol Vis Sci. 2009;50: 3771-3777.
13. Li Y, Aroca-Aguilar JD, Ghosh S, Sanchez-Sanchez F, Escribano J, Coca-Prados M. Interaction of myocilin with the C-terminal region of hevin. Biochem Biophys Res Commun. 2006;339:797-804.
14. Kirwan RP, Wordinger RJ, Clark AF, O'Brien CJ. Differential global and extra-cellular matrix focused gene expression patterns between normal and glaucomatous human lamina cribrosa cells. Mol Vis. 2009;15:76-88.
15. Fuchshofer R, Tamm ER. Modulation of extracellular matrix turnover in the trabecular meshwork. Exp Eye Res. 2009;88:683-688.
16. Inatani M, Tanihara H, Katsuta H, Honjo M, Kido N, Honda Y. Transforming growth factor-beta 2 levels in aqueous humor of glaucomatous eyes. Graefes Arch Clin Exp Ophthalmol. 2001;239: 109-113.
17. Ochiai Y, Ochiai H. Higher concentration of transforming growth factor-beta in aqueous humor of glaucomatous eyes and diabetic eyes. Jpn J Ophthalmol. 2002;46:249-253.
18. Picht G, Welge-Luessen U, Grehn F, Lutjen-Drecoll E. Transforming growth factor beta 2 levels in the aqueous humor in different types of glaucoma and the relation to filtering bleb development. Graefes Arch Clin Exp Ophthalmol. 2001;239:199-207.
19. Tripathi RC, Li J, Chan WF, Tripathi BJ. Aqueous humor in glaucomatous eyes contains an increased level of TGF-beta 2. Exp Eye Res. 1994;59:723-727.
20. Chiquet-Ehrismann R. Tenascins. Int J Biochem Cell Biol. 2004; 36:986-990.
21. Chiquet-Ehrismann R, Chiquet M. Tenascins: regulation and putative functions during pathological stress. J Pathol. 2003;200:488-499.
22. Keller KE, Kelley MJ, Acott TS. Extracellular matrix gene alternative splicing by trabecular meshwork cells in response to mechanical stretching. Invest Ophthalmol Vis Sci. 2007;48:1164-1172.
23. Duvall CL, Taylor WR, Weiss D, Wojtowicz AM, Guldberg RE. Impaired angiogenesis, early callus formation, and late stage remodeling in fracture healing of osteopontin-deficient mice. J Bone Miner Res. 2007;22:286-297.
24. Giachelli CM, Steitz S. Osteopontin: a versatile regulator of inflammation and biomineralization. Matrix Biol. 2000;19:615-622.
25. Klingel K, Kandolf R. Osteopontin: a biomarker to predict the outcome of inflammatory heart disease. Semin Thromb Hemost. 2010;36:195-202.
26. Waller AH, Sanchez-Ross M, Kaluski E, Klapholz M. Osteopontin in cardiovascular disease: a potential therapeutic target. Cardiol Rev. 2010;18:125-131.
27. Scatena M, Liaw I, Giachelli CM. Osteopontin: a multifunctional molecule regulating chronic inflammation and vascular disease. Arterioscler Thromb Vasc Biol. 2007;27:2302-2309.
28. Uede T, Katagiri Y, Iizuka J, Murakami M. Osteopontin, a coordinator of host defense system: acytokine or an extracellular matrix adhesive protein. Microbiol Immunol. 1997;41:641-648.
29. Wang KX, Denhardt DT. Osteopontin: role in immune regulation and stress responses. Cytokine Growth Factor Rev. 2008;19:333-345.
30. Chidlow G, Wood JP, Manavis J, Osborne NN, Casson RJ. Expression of osteopontin in the rat retina: effects of excitotoxic and ischemic injuries. Invest Ophthalmol Vis Sci. 2008;49:762-771.
31. Fujita N, Fujita S, Okada Y, et al. Impaired angiogenic response in the corneas of mice lacking osteopontin. Invest Ophthalmol Vis Sci. 2010;51:790-794.
32. Miyazaki K, Okada Y, Yamanaka O, et al. Corneal wound healing in an osteopontin-deficient mouse. Invest Ophthalmol Vis Sci. 2008; 49:1367-1375.
33. Saika S, Shirai K, Yamanaka O, et al. Loss of osteopontin perturbs the epithelial-mesenchymal transition in an injured mouse lens epithelium. Lab Invest. 2007;87:130-138.
34. Gonzalez P, Epstein DL, Borras T. Characterization of gene expression in human trabecular meshwork using single-pass sequencing of 1060 clones. Invest Ophthalmol Vis Sci. 2000;41:3678-3693.
35. Gonzalez P, Zigler JS Jr, Epstein DL, Borras T. Identification and isolation of differentially expressed genes from very small tissue samples. BioTechniques. 1999;26:884-886, 888-892.
36. Tomarev SI, Wistow G, Raymond V, Dubois S, Malyukova I. Gene expression profile of the human trabecular meshwork: NEIBank sequence tag analysis. Invest Ophthalmol Vis Sci. 2003;44:2588-2596.
37. Borras T, Comes N. Evidence for a calcification process in the trabecular meshwork. Exp Eye Res. 2009;88:738-746.
38. Xue W, Comes N, Borras T. Presence of an established calcification marker in trabecular meshwork tissue of glaucoma donors. Invest Ophthalmol Vis Sci. 2007;48:3184-3194.
39. Last JA, Pan T, Ding Y, et al. Elastic modulus determination of normal and glaucomatous human trabecular meshwork. Invest Ophthalmol Vis Sci. 2011;52:2147-2152.
40. Chowdhury UR, Madden BJ, Charlesworth MC, Fautsch MP. Proteome analysis of human aqueous humor. Invest Ophthalmol Vis Sci. 2010;51:4921-4931.
41. Ezzat MK, Howell KG, Bahler CK, et al. Characterization of monoclonal antibodies against the glaucoma-associated protein myocilin. Exp Eye Res. 2008;87:376-384.
42. Fautsch MP, Bahler CK, Jewison DJ, Johnson DH. Recombinant TIGR/MYOC increases outflow resistance in the human anterior segment. Invest Ophthalmol Vis Sci. 2000;41:4163-4168.
43. Stamer WD, Seftor RE, Williams SK, Samaha HA, Snyder RW. Isolation and culture of human trabecular meshwork cells by extracellular matrix digestion. Curr Eye Res. 1995;14:611-617.
44. Saeki T, Aihara M, Ohashi M, Araie M. The efficacy of TonoLab in detecting physiological and pharmacological changes of mouse intraocular pressure: comparison with TonoPen and microneedle manometry. Curr Eye Res. 2008;33:247-252.
45. Wang WH, Millar JC, Pang IH, Wax MB, Clark AF. Noninvasive measurement of rodent intraocular pressure with a rebound tonometer. Invest Ophthalmol Vis Sci. 2005;46:4617-4621.
46. Aihara M, Lindsey JD, Weinreb RN. Reduction in intraocular pressure in mouse eyes treated with latanoprost. Invest Ophthalmol Vis Sci. 2002;43:146-150.
47. Savinova OV, Sugiyama F, Martin JE, et al. Intraocular pressure in genetically distinct mice: an update and strain survey. BMC Genet. 2001;2:12.
48. Brandt JD. Corneal thickness in glaucoma screening, diagnosis, and management. Curr Opin Ophthalmol. 2004;15:85-89.
49. Escribano J, Ortego J, Coca-Prados M. Isolation and characterization of cell-specific cDNA clones from a subtractive library of the ocular ciliary body of a single normal human donor: transcription and synthesis of plasma proteins. J Biochem. 1995;118:921-931.
50. Kazanecki CC, Uzwiak DJ, Denhardt DT. Control of osteopontin signaling and function by post-translational phosphorylation and protein folding. J Cell Biochem. 2007;102:912-924.
51. Singh K, DeVouge MW, Mukherjee BB. Physiological properties and differential glycosylation of phosphorylated and nonphosphorylated forms of osteopontin secreted by normal rat kidney cells. J Biol Chem. 1990;265:18696-18701.
52. Kang MH, Oh DJ, Rhee DJ. Effect of hevin deletion in mice and characterization in trabecular meshwork. Invest Ophthalmol Vis Sci. 2011;52:2187-2193.
53. Flugel-Koch C, Ohlmann A, Fuchshofer R, Welge-Lussen U, Tamm ER. Thrombospondin-1 in the trabecular meshwork: localization in normal and glaucomatous eyes, and induction by TGF-b1 and dexamethasone in vitro. Exp Eye Res. 2004;79:649-663.
54. Johnson EC, Jia L, Cepurna WO, Doser TA, Morrison JC. Global changes in optic nerve head gene expression after exposure to elevated intraocular pressure in a rat glaucoma model. Invest Ophthalmol Vis Sci. 2007;48:3161-3177.
55. Fan BJ, Wang DY, Tham CC, Lam DS, Pang CP. Gene expression profiles of human trabecular meshwork cells induced by triamcinolone and dexamethasone. Invest Ophthalmol Vis Sci. 2008;49: 1886-1897.
56. Rozsa FW, Reed DM, Scott KM, et al. Gene expression profile of human trabecular meshwork cells in response to long-term dexamethasone exposure. Mol Vis. 2006;12:125-141.
57. Kurokawa M, Konno S, Matsukura S, et al. Effects of corticosteroids on osteopontin expression in a murine model of allergic asthma. Int Arch Allergy Immunol. 2009;149(suppl 1):7-13.
58. Park JB. The effects of dexamethasone, ascorbic acid, and betaglycerophosphate on osteoblastic differentiation by regulating estrogen receptor and osteopontin expression. J Surg Res. In press.
59. Giachelli CM. Inducers and inhibitors of biomineralization: lessons from pathological calcification. Orthod Craniofac Res. 2005;8: 229-231.
60. Steitz SA, Speer MY, McKee MD, et al. Osteopontin inhibits mineral deposition and promotes regression of ectopic calcification. Am J Pathol. 2002;161:2035-2046.
61. Schneider S, Yochim J, Brabender J, et al. Osteopontin but not osteonectin messenger RNA expression is a prognostic marker in curatively resected non-small cell lung cancer. Clin Cancer Res. 2004;10:1588-1596.
62. Yiu GK, Chan WY, Ng SW, et al. SPARC (secreted protein acidic and rich in cysteine) induces apoptosis in ovarian cancer cells. Am J Pathol. 2001;159:609-622.
63. Birke MT, Neumann C, Birke K, Kremers J, Scholz M. Changes of osteopontin (OPN) in the aqueous humor of the DBA2/J glaucoma model correlated with optic nerve and RGC degenerations. Invest Ophthalmol Vis Sci. 2010;51:5759-5767.
64. Knippenberg M, Helder MN, de Blieck-Hogervorst JM, Wuisman PI, Klein-Nulend J. Prostaglandins differentially affect osteogenic differentiation of human adipose tissue-derived mesenchymal stem cells. Tissue Eng. 2007;13:2495-2503.
65. Christensen B, Schack L, Klaning E, Sorensen ES. Osteopontin is cleaved at multiple sites close to its integrin-binding motifs in milk and is a novel substrate for plasmin and cathepsin D. J Biol Chem. 2010;285:7929-7937.
66. Beninati S, Senger DR, Cordella-Miele E, et al. Osteopontin: its transglutaminase-catalyzed posttranslational modifications and cross-linking to fibronectin. J Biochem. 1994;115:675-682.
67. Christensen B, Nielsen MS, Haselmann KF, Petersen TE, Sorensen ES. Post-translationally modified residues of native human osteopontin are located in clusters: identification of 36 phosphorylation and five O-glycosylation sites and their biological implications. Biochem J. 2005;390:285-292.
68. Miwa HE, Gerken TA, Jamison O, Tabak LA. Isoform-specific O-glycosylation of osteopontin and bone sialoprotein by polypeptide N-acetylgalactosaminyltransferase-1. J Biol Chem. 2010;285: 1208-1219.
69. Kaartinen MT, Murshed M, Karsenty G, McKee MD. Osteopontin upregulation and polymerization by transglutaminase 2 in calcified arteries of matrix Gla protein-deficient mice. J Histochem Cytochem. 2007;55:375-386.
70. Agnihotri R, Crawford HC, Haro H, Matrisian LM, Havrda MC, Liaw L. Osteopontin, a novel substrate for matrix metalloproteinase-3 (stromelysin-1) and matrix metalloproteinase-7 (matrilysin). J Biol Chem. 2001;276:28261-28267.
71. Senger DR, Perruzzi CA, Papadopoulos A. Elevated expression of secreted phosphoprotein I (osteopontin, 2ar) as a consequence of neoplastic transformation. Anticancer Res. 1989;9:1291-1299.
72. Senger DR, Perruzzi CA, Papadopoulos A, Tenen DG. Purification of a human milk protein closely similar to tumor-secreted phosphoproteins and osteopontin. Biochim Biophys Acta. 1989;996: 43-48.
73. Aihara M, Lindsay JD, Weinreb RN. Aqueous humor dynamics in mice. Invest Ophthalmol Vis Sci. 2003;55:5168-5173.
74. Nissirios N, Goldblum D, Rohrer K, Mittag T, Danias J. Noninvasive determination of intraocular pressure (IOP) in nonsedated mice of 5 different inbred strains J Glaucoma. 2007;16:57-61.